Pentavalent technetium-99m-dimercaptosuccinic acid scintigraphy in renal osteodystrophy. 1998

T Higuchi, and T Hirano, and T Inoue, and J Aoki, and K Ueki, and R Wakamatsu, and S Yano, and T Naruse, and K Endo
Department of Nuclear Medicine, Gunma University School of Medicine, Mebashi, Japan.

Pentavalent 99mTc-dimercaptosuccinic acid (DMSA) scintigraphy and 99mTc-hydroxymethylene diphosphonate (HMDP) bone scan were performed in one patient with renal osteodystrophy (ROD) before and after vitamin D3 pulse therapy. The bone scan showed diffusely increased tracer uptake in the whole skeleton, and no change of tracer distribution was noted before or after vitamin D3 pulse therapy. However, 99mTc(V)-DMSA scintigraphy revealed diffusely increased tracer uptake in the whole skeleton before therapy, and markedly decreased tracer uptake in the bones was seen at 5 mo after therapy. Increased uptake of 99mTc(V)-DMSA was observed at 7 mo after therapy, which reflected the laboratory findings. Technetium-99m-(V)-DMSA scintigraphy appeared to be more sensitive than the conventional 99mTc-HMDP bone scan in assessing the characteristics and therapeutic effect of bone disease in ROD.

UI MeSH Term Description Entries
D011877 Radionuclide Imaging The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph. Gamma Camera Imaging,Radioisotope Scanning,Scanning, Radioisotope,Scintigraphy,Scintiphotography,Imaging, Gamma Camera,Imaging, Radionuclide
D012080 Chronic Kidney Disease-Mineral and Bone Disorder Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders. Renal Osteodystrophy,Renal Rickets,Rickets, Renal,CKD-MBD,Osteodystrophy, Renal,Chronic Kidney Disease Mineral and Bone Disorder,Osteodystrophies, Renal,Renal Osteodystrophies
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013669 Technetium Tc 99m Medronate A gamma-emitting radionuclide imaging agent used primarily in skeletal scintigraphy. Because of its absorption by a variety of tumors, it is useful for the detection of neoplasms. Tc-99m MDP,Technetium Methylene Diphosphonate,99mTc-MDP,99mTc-Methylene Diphosphonate,Tc-99 Medronate,Tc-99m Methylene Diphosphonate,Technetium Tc 99m Methylenediphosphonate,99mTc Methylene Diphosphonate,Diphosphonate, 99mTc-Methylene,Diphosphonate, Tc-99m Methylene,Diphosphonate, Technetium Methylene,Medronate, Tc-99,Methylene Diphosphonate, Tc-99m,Methylene Diphosphonate, Technetium,Tc 99 Medronate,Tc 99m Methylene Diphosphonate
D019275 Radiopharmaceuticals Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) Radiopharmaceutical
D019783 Technetium Tc 99m Dimercaptosuccinic Acid A nontoxic radiopharmaceutical that is used in the diagnostic imaging of the renal cortex. 99Tc-Succimer,99mTc-DMSA,99mTc-Dimercaptosuccinic Acid,99m-Tc-Dimercaptosuccinic Acid,99mTc-Dimercaptosuccinate,Tc-99m Dimercaptosuccinic Acid,Technetium Tc 99m Succimer,Technetium-99m-DMSA,Technetium-99m-Dimercaptosuccinic Acid,99Tc Succimer,99m Tc Dimercaptosuccinic Acid,99mTc DMSA,99mTc Dimercaptosuccinate,99mTc Dimercaptosuccinic Acid,Acid, 99m-Tc-Dimercaptosuccinic,Acid, 99mTc-Dimercaptosuccinic,Acid, Tc-99m Dimercaptosuccinic,Acid, Technetium-99m-Dimercaptosuccinic,Dimercaptosuccinic Acid, Tc-99m,Tc 99m Dimercaptosuccinic Acid,Technetium 99m DMSA,Technetium 99m Dimercaptosuccinic Acid

Related Publications

T Higuchi, and T Hirano, and T Inoue, and J Aoki, and K Ueki, and R Wakamatsu, and S Yano, and T Naruse, and K Endo
September 1992, Postgraduate medical journal,
T Higuchi, and T Hirano, and T Inoue, and J Aoki, and K Ueki, and R Wakamatsu, and S Yano, and T Naruse, and K Endo
May 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
T Higuchi, and T Hirano, and T Inoue, and J Aoki, and K Ueki, and R Wakamatsu, and S Yano, and T Naruse, and K Endo
May 1998, Pediatric nephrology (Berlin, Germany),
T Higuchi, and T Hirano, and T Inoue, and J Aoki, and K Ueki, and R Wakamatsu, and S Yano, and T Naruse, and K Endo
January 2006, Hellenic journal of nuclear medicine,
T Higuchi, and T Hirano, and T Inoue, and J Aoki, and K Ueki, and R Wakamatsu, and S Yano, and T Naruse, and K Endo
July 1995, European journal of endocrinology,
T Higuchi, and T Hirano, and T Inoue, and J Aoki, and K Ueki, and R Wakamatsu, and S Yano, and T Naruse, and K Endo
August 1995, Annals of nuclear medicine,
T Higuchi, and T Hirano, and T Inoue, and J Aoki, and K Ueki, and R Wakamatsu, and S Yano, and T Naruse, and K Endo
July 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
T Higuchi, and T Hirano, and T Inoue, and J Aoki, and K Ueki, and R Wakamatsu, and S Yano, and T Naruse, and K Endo
June 2002, Clinical endocrinology,
T Higuchi, and T Hirano, and T Inoue, and J Aoki, and K Ueki, and R Wakamatsu, and S Yano, and T Naruse, and K Endo
December 1996, European journal of nuclear medicine,
T Higuchi, and T Hirano, and T Inoue, and J Aoki, and K Ueki, and R Wakamatsu, and S Yano, and T Naruse, and K Endo
January 2017, Hellenic journal of nuclear medicine,
Copied contents to your clipboard!